NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for resected pancreatic cancer

May 20 2010NewsGuard 100/100 Score

NewLink Genetics Corporation today announced that preliminary data from its Phase 2 clinical trial evaluating the effect of HyperAcute®-Pancreas immunotherapy in patients with resected pancreatic cancer will be presented during a poster session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting held June 4-8, 2010 in Chicago, Illinois. A summary of the company's ASCO presentation is below.

Hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer improves disease-free and overall survival: preliminary analysis of phase 2 data

  • General poster session: Sunday, June 6, 2010, 2:00 p.m. – 6:00 p.m. Central Time (CT)
  • Abstract # 54004 (poster board # 20F)
  • First Author: Dr. Jeffrey M. Hardacre, University Hospitals Case Medical Center, Cleveland, Ohio

SOURCE NewLink Genetics Corporation

Posted in: Medical Procedure News | Medical Condition News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Female firefighters face elevated breast cancer risks due to toxic exposures
AI-powered tool predicts gene activity in cancer cells from biopsy images
Study shows AI can predict prognosis in triple-negative breast cancer
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation
Study shows cannabis as a genotoxic substance with cancer risks
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients
Air pollution linked to head and neck cancer risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Golgi apparatus plays crucial role in enhancing T-cell function against cancer